Please assess the completion status of the following clinical trial:

Trial Title: Carboplatin With or Without Gemcitabine in Treating Patients With Advanced Ovarian Epithelial Cancer That Has Not Responded to Previous Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed ovarian epithelial carcinoma not amenable to curative surgery or radiotherapy~  * Evidence of recurrence or progression 6 months after discontinuation of prior first-line platinum-containing regimen~* No tumor of borderline malignancy~* Evaluable disease outside previously irradiated area~* No CNS metastases~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* ECOG 0-2~Life expectancy:~* At least 12 weeks~Hematopoietic:~* Neutrophil count at least 1,500/mm3~* Platelet count at least 100,000/mm3~Hepatic:~* Not specified~Renal:~* Glomerular filtration rate greater than 50 mL/min~Other:~* No concurrent active infection~* No other primary malignancy except carcinoma in situ of the cervix or adequately treated basal cell skin cancer~* No other concurrent serious systemic disorder~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* See Disease Characteristics~* No more than 1 prior platinum-based chemotherapy regimen~* No prior gemcitabine~* No other concurrent cytotoxic or antineoplastic treatment~Endocrine therapy:~* At least 3 weeks since prior hormonal therapy~* Concurrent hormone replacement therapy allowed~* Concurrent steroid antiemetics allowed~Radiotherapy:~* See Disease Characteristics~* At least 3 weeks since prior radiotherapy (limited to the small pelvis)~* Concurrent palliative radiotherapy to nontarget lesions allowed~Surgery:~* See Disease Characteristics~Other:~* At least 3 weeks since other prior investigational agents

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).